share_log

Reneo Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Braden M Leonard(5.1%),BML Investment Partners, L.P.(4.1%)

SEC announcement ·  Jan 17 00:00
Summary by Moomoo AI
On January 10, 2024, BML Investment Partners, L.P. filed a Schedule 13G with the SEC, indicating a significant ownership stake in Reneo Pharmaceuticals, Inc. The filing revealed that BML Investment Partners, along with Braden M Leonard, collectively hold 1,694,229 shares of Reneo Pharmaceuticals' common stock, which represents 5.1% of the company's class of securities. Braden M Leonard, identified as the Managing Member, has sole voting and dispositive power over 330,000 shares and shared power over an additional 1,364,229 shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, and the information provided is not deemed to be 'filed' for liability purposes under Section 18 of the Act but is subject to all other provisions of the Act. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Reneo Pharmaceuticals.
On January 10, 2024, BML Investment Partners, L.P. filed a Schedule 13G with the SEC, indicating a significant ownership stake in Reneo Pharmaceuticals, Inc. The filing revealed that BML Investment Partners, along with Braden M Leonard, collectively hold 1,694,229 shares of Reneo Pharmaceuticals' common stock, which represents 5.1% of the company's class of securities. Braden M Leonard, identified as the Managing Member, has sole voting and dispositive power over 330,000 shares and shared power over an additional 1,364,229 shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, and the information provided is not deemed to be 'filed' for liability purposes under Section 18 of the Act but is subject to all other provisions of the Act. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Reneo Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more